Eupraxia Pharmaceuticals share price logo

Eupraxia Pharmaceuticals

NASDAQ: EPRX

Small Cap

$8.40

+0.90

(+12.00%)

as on

Eupraxia Pharmaceuticals Stock Performance

as on September 5, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $7.39
    $8.38
    downward going graph

    12.02%

    Downside

    -0.24%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $5.15
    $9.32
    downward going graph

    38.69%

    Downside

    10.95%

    Upside

    downward going graph

Eupraxia Pharmaceuticals share price movements today

Previous Close
$7.50
Open
$7.45
Volume
3.8M
Market Cap
$492.2M
Day's Low - High
$7.39 - $8.38
52 Week Low - High
$5.15 - $9.32

Eupraxia Pharmaceuticals Historical Returns

1 Month Return
+ 15.03 %
3 Month Return
+ 16.28 %
1 Year Return
+ 39.93 %
3 Year Return
0 %
5 Year Return
0 %

Eupraxia Pharmaceuticals Stock Fundamentals & Key Indicators

Check Eupraxia Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$492.2M

EPS (TTM)

-1.02

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-7.36

Industry PE ratio

-6.69

PEG Ratio

0.3339435671512543

EBITDA

-55.8M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-45.29%

Eupraxia Pharmaceuticals Stock Valuation

Track how Eupraxia Pharmaceuticals P/E has moved over time to understand its valuation trends.

Eupraxia Pharmaceuticals in the last 5 years

  • Overview

  • Trends

Lowest (-9.83x)

December 31, 2025

Today (-9.83x)

December 31, 2025

Industry (-6.69x)

December 31, 2025

Highest (-1.52x)

December 31, 2021

LowHigh

Today’s Price to Earnings Ratio: -9.83x

Eupraxia Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Eupraxia Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$492.2MNA-7.360.00%NA
BUY$44.6B614.61%NA0.00%NA
BUY$141.1B181.73%32.2186.04%NA
BUY$60.2B-64.27%-18.66-12.57%NA
BUY$84.8B24.12%20.1484.86%0.44%

Stock Returns calculator for Eupraxia Pharmaceuticals Stock including INR - Dollar returns

The Eupraxia Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Eupraxia Pharmaceuticals investment value today

Current value as on today

₹1,68,312

Returns

₹68,312

(+68.31%)

Returns from Eupraxia Pharmaceuticals Stock

₹56,716 (+56.72%)

Dollar Impact

₹11,595 (+11.6%)

Analyst Recommendation on Eupraxia Pharmaceuticals Stock

Based on 7 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 7 analysts, 100% of analysts recommend a 'BUY' rating for Eupraxia Pharmaceuticals. Average target price of $16.35

Eupraxia Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Eupraxia Pharmaceuticals.

What analysts predicted

48.62%UPSIDE

Target Price

$16.35

Current Price

$8.4

Analyzed by

7 Analysts

Target

$16.35

Eupraxia Pharmaceuticals target price $16.35, a slight upside of 48.62% compared to current price of $8.4. According to 7 analysts rating.

Indian Investors' Interest in Eupraxia Pharmaceuticals Stock

Search interest for Eupraxia Pharmaceuticals Stock has decreased by -78% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-78% versus previous 30 day period

Eupraxia Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-6
-6
-6
-7
-7
-8
-6
-16
-15
-17
EBITDA
-5
-
-4
-7
-4
-6
-6
-16
-15
-17
Interest Expense
0
0
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-
-6
-5
-7
-6
-8
-6
-16
-12
-14
Income Tax Expense
0
0
-
0
0
0
0
0
0
0
Net Income
-6
-4
-5
-7
-6
-8
-6
-16
-12
-14
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Eupraxia Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Mar 2024
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
-
-
-
Gross Profit
0
0
0
0
0
0
0
0
0
Operating Income
-4
-12
-6
-2
-18
-23
-28
-25
-39
EBITDA
-4
-11
-5
-2
-21
-22
-28
-23
-38
Interest Expense
0
0
1
1
1
1
1
0
-
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-4
-14
-7
-4
-23
-23
-28
-24
-39
Income Tax Expense
-
-
-
-
-
-
0
-
0
Net Income
-4
-13
-7
-3
-22
-23
-28
-24
-39
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Eupraxia Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-6
-4
-4
-7
-6
-8
-4
-16
-12
-14
Operating Cash Flow
-6
-7
-7
-5
-6
-8
-3
-9
-9
-12
Investing Cash Flow
0
0
0
0
0
0
0
0
-78
0
Financing Cash Flow
23
-4
-3
31
0
0
52
1
67
7
Change in Cash
11
-12
-10
24
-5
-7
49
-9
-20
-5

Eupraxia Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Mar 2024
Dec 2024
Dec 2025
Net Income
-4
-14
-7
-4
-23
-23
-28
-25
-38
Operating Cash Flow
-5
-8
-5
0
-14
-18
-21
-29
-29
Investing Cash Flow
0
0
-1
0
-14
8
0
0
0
Financing Cash Flow
9
5
7
0
49
13
21
45
77
Change in Cash
3
-3
0
-1
20
3
0
13
45

Mutual Funds that own Eupraxia Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Eupraxia Pharmaceuticals.

Funds
Holdings
Shares Held
Fidelity Concord Street Trust
0.027015%
17805

Global Institutional Holdings in Eupraxia Pharmaceuticals

Funds
Holdings
Michael Rockefeller
1.13%
Dennis J Purcell
0.49%
Dynamic
0.09%
iShares
0.07%

Eupraxia Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 20 February

    Sat, 01:40 AM

    -

    Eupraxia Pharmaceuticals closes US$63.2 million public offering, expanding pipeline and advancing clinical trials for EP-104GI.

Insights on Eupraxia Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, EPRX stock has moved up by 25.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 479.0% return, outperforming this stock by 423.2%

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
OrganisationEupraxia Pharmaceuticals
Headquarters2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4
IndustryBiotechnology
CEODr. James A. Helliwell FRCPC, M.D.
E-voting on sharesClick here to vote

Key Management of Eupraxia Pharmaceuticals

Name

Title

Dr. Jeffrey Millard Ph.d.

Executive Vice President of Technical Operations

Dr. James A. Helliwell FRCPC, M.D.

CEO & Director

Mr. Alexander John Rothwell Eng., M.B.A.

Chief Financial Officer

Mr. Paul Anthony Brennan B.Sc., M.Sc.

Chief Corporate Development Officer

Ms. Wajida Leclerc B.A., CCP, CHRP

Executive Vice President Corporate Services & People

Mr. Alex Therien

Executive VP of R&D

Dr. Jeymi Tambiah M.S.

Chief Medical Officer

FAQs

What is Eupraxia Pharmaceuticals share price today?

Eupraxia Pharmaceuticals share price today is $8.40 as on at the close of the market. Eupraxia Pharmaceuticals share today touched a day high of $8.38 and a low of $7.39.

What is the 52 week high and 52 week low for Eupraxia Pharmaceuticals share?

Eupraxia Pharmaceuticals share touched a 52 week high of $9.32 on and a 52 week low of $5.15 on . Eupraxia Pharmaceuticals stock price today i.e. is closed at $8.40,which is 9.87% down from its 52 week high and 63.10% up from its 52 week low.

What is Eupraxia Pharmaceuticals's market capitalisation today?

Eupraxia Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Eupraxia Pharmaceuticals Stock (EPRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Eupraxia Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Eupraxia Pharmaceuticals Shares that will get you 0.1786 shares as per Eupraxia Pharmaceuticals share price of $8.40 per share as on September 5, 2026 at 8:45 am IST.

What is the minimum amount required to buy Eupraxia Pharmaceuticals Stock (EPRX) from India?

Indian investors can start investing in Eupraxia Pharmaceuticals (EPRX) shares with as little as ₹94.49 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹944.90 in Eupraxia Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Eupraxia Pharmaceuticals share’s latest price of $8.40 as on September 5, 2026 at 8:45 am IST, you will get 1.1905 shares of Eupraxia Pharmaceuticals. Learn more about fractional shares .